Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis unveils plans to expand oncology portfolio

Novartis unveils plans to expand oncology portfolio

9th December 2009

Novartis has unveiled its intentions to further build upon its oncology portfolio in a bid to strengthen its expertise in this area of therapy.

The firm aims to explore new indications for marketed drugs, progress with 16 new molecular entities and already has two treatments in development and on-schedule as of the end of 2009 – Tasigna and Zometa.

Joe Jimenez, chief executive officer of Novartis’ pharmaceuticals division, commented: “The benefits of our sustained research and devlopment investments are reflected in the nearly 30 major regulatory approvals achieved so far in 2009 in the US, Europe, Japan and China.”

He added that there are currently 27 projects undergoing late-stage clinical trials and eight further initiatives are awaiting regulatory verdicts.

In other Novartis news, the firm announced last month that the European commission has approved Onbrez Breezhaler (QAB149 or indacaterol) – its once-daily maintenance bronchodilator – for distribution in the EU.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.